IRLA · XBRL financial data

Quince Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (IRLA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26†Mar 31, 2026	Q2 FY26†Jun 30, 2026
Research and development	1,431	3,434*	3,702	4,147	4,916	5,825*	8,145	6,553	8,083	12,601*	6,845	5,461
General and administrative	4,663	4,909*	4,971	4,695	3,630	4,284*	4,789	3,342	3,281	3,635*	4,267	16,626
Total operating expenses	6,094	9,921*	11,218	28,192	5,863	12,012*	14,858	10,427	13,430	19,353*	14,590	79,782
Operating income (loss)	(6,094)	(9,921)*	(11,218)	(28,192)	(5,863)	(12,012)*	(14,858)	(10,427)	(13,430)	(19,353)*	(14,590)	(79,782)
Interest income	959	1,014*	887	823	683	536*	406	311	300	227*	160	584
Other income (expense)	(216)	402*	(399)	91	150	(518)*	(87)	(29)	(58)	660*	1,719	152
Income tax expense (benefit)	0	445*	31	36	13	7*	47	67	(46)	3,146*	(5,339)	75
Net income (loss)	(5,351)	(8,894)*	(11,149)	(27,729)	(5,492)	(12,458)*	(15,030)	(16,049)	(13,442)	(39,458)*	35,912	(75,488)
Earnings per share, basic USD per share	(0.15)	(0.22)*	(0.26)	(0.64)	(0.13)	(0.28)*	(0.34)	(0.34)	(0.25)	(0.71)*	3.60	(12.31)
Earnings per share, diluted USD per share	(0.15)	(0.22)*	(0.26)	(0.64)	(0.13)	(0.28)*	(0.34)	(0.34)	(0.25)	(0.71)*	2.88	(12.31)
Weighted average shares, basic thousands of shares	36,073	41,058*	43,010	43,096	43,164	43,774*	43,941	46,686	53,951	55,638*	9,120	6,133
Weighted average shares, diluted thousands of shares	36,073	41,058*	43,010	43,096	43,164	43,774*	43,941	46,686	53,951	55,638*	9,190	6,133

† Share count changed about 3x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/10 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/16 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (IRLA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26†Mar 31, 2026	Q2 FY26†Jun 30, 2026
Cash and cash equivalents	20,823	20,752	21,813	7,890	2,675	6,212	7,771	16,826	6,452	5,809	18,163	115,981
Short-term investments	—	—	—	—	—	—	—	—	—	11,943	0	0
Marketable securities	61,593	54,307	46,010	51,555	45,172	34,572	—	—	—	11,943	0	0
Marketable securities, non-current	0	0	—	—	—	—	—	—	—	—	—	—
Prepaid and other current assets	1,448	2,381	2,616	3,993	3,871	3,252	2,230	2,637	2,914	5,144	7,417	7,430
Total current assets	85,173	77,440	70,439	63,438	51,718	44,036	33,829	37,345	29,202	22,896	25,580	123,411
Property and equipment, net	5	234	234	246	208	315	448	573	616	595	550	506
Right-of-use asset	48	385	576	554	559	498	493	507	481	453	415	0
Goodwill	0	17,625	17,245	0	0	0	—	—	0	—	—	—
Total assets	85,386	167,900	159,292	134,829	126,519	114,478	107,089	117,210	109,899	93,523	26,623	123,995
Accounts payable	409	2,033	2,070	2,405	1,622	2,903	3,008	1,759	3,403	2,223	5,392	4,636
Accrued liabilities	1,844	3,436	3,020	2,916	3,803	4,375	5,348	5,708	5,121	10,608	3,376	3,864
Current portion of long-term debt	—	—	—	—	—	0	—	—	17,520	18,026	0	0
Total current liabilities	2,253	9,572	9,838	10,321	5,425	7,278	8,356	7,467	26,044	43,226	8,768	8,500
Lease liability, non-current	—	321	480	453	450	394	383	387	359	330	293	0
Total liabilities	2,253	82,816	85,115	87,861	81,587	84,332	88,508	105,474	108,840	129,237	10,951	15,508
Accumulated deficit	(310,750)	(319,644)	(330,793)	(358,522)	(364,014)	(376,472)	(391,502)	(407,551)	(420,993)	(460,451)	(424,539)	(500,027)
Total stockholders' equity	83,133	85,084	74,177	46,968	44,932	30,146	18,581	11,736	1,059	(35,714)	15,672	(35,324)
Total liabilities and equity	85,386	167,900	159,292	134,829	126,519	114,478	107,089	117,210	109,899	93,523	26,623	123,995
Common shares outstanding (cover page) thousands of shares	42,869	43,215	43,215	43,277	44,002	44,002	45,469	53,714	55,681	163,008	16,301	1,017

† Share count changed about 3x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/10 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/16 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (IRLA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26†Mar 31, 2026	Q2 FY26†Jun 30, 2026
Net income (loss)	(5,351)	(8,894)*	(11,149)	(27,729)	(5,492)	(12,458)*	(15,030)	(16,049)	(13,442)	(39,458)*	35,912	(75,488)
Stock-based compensation	1,331*	1,086*	1,274	1,223*	1,124*	1,125*	1,386	1,273*	1,255*	1,191*	1,286	12,093*
Net cash from operating activities	(4,818)*	(6,078)*	(8,353)	(8,739)*	(7,260)*	(7,552)*	(9,601)	(11,415)*	(9,928)*	(10,481)*	(7,627)	(18,887)*
Purchases of property and equipment	0*	24*	39	39*	46*	133*	148	126*	74*	4*	0	0*
Net cash from investing activities	3,635*	5,390*	8,914	(4,978)*	7,105*	10,867*	10,898	6,039*	(1,781)*	8,071*	12,000	8,001*
Proceeds from issuing common stock	0*	0*	—	—	—	—	—	—	—	—	—	—
Net cash from financing activities	10*	57*	190	35*	(5,000)*	0*	87	14,412*	1,376*	2,034*	9,443	108,933*
Net change in cash	(1,018)*	(880)*	1,061	(13,923)*	(5,215)*	3,537*	1,559	9,055*	(10,374)*	(643)*	12,354	97,818*

† Share count changed about 3x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/10 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/16 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Quince Therapeutics	115,981	not reported	(18,887)*	1.0M	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Veru	23,880	not reported	(5,467)*	17.1M	4.4 quarters	Q3 FY26 10-QJun 30, 2026
Lifevantage	14,920	42,377*	4,767*	12.5M	—	Q4 FY26 10-KJun 30, 2026
Whitehawk Therapeutics	85,234	0	(14,529)*	57.0M	13.1 quarters	Q2 FY26 10-QJun 30, 2026
Medicinova	25,416	458	(1,920)*	49.2M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings	23,370	not reported	(29,626)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
PDS Biotechnology	5,596	not reported	(2,793)*	56.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Sutro Biopharma	54,335	9,839	(38,290)*	16.6M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
iBio	56,395	0*	(6,228)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.